Natural Product (NP) Details
| General Information of the NP (ID: NP5651) | |||||
|---|---|---|---|---|---|
| Name |
Morusin
|
||||
| Synonyms |
Morusin; 62596-29-6; Mulberrochromene; TCMDC-124149; UNII-T4VGD5NP9B; NSC649220; T4VGD5NP9B; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one; CHEBI:7005; CHEMBL464006; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)pyrano[2,3-f]chromen-4(8H)-one; 4H,8H-Benzo(1,2-b:3,4-b')dipyran-4-one, 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-; Morusin, 3; NSC 649220; MLS000697591; MEGxp0_001039; SCHEMBL2562778; ACon1_001205; cid_5281671; DTXSID70211641; HMS2271K05; BCP16494; HY-N0622; ZINC5195808; BDBM50242014; LMPK12110912; MFCD09953814; AKOS032962066; CS-6885; NSC-649220; AK169967; LS-15105; SMR000470930; FT-0686661; N2266; W1523; A14647; C10106; BRD-K40169295-001-01-2; Q27107393; 2-(2,4-dihydroxyphenyl)-5-hydroxy-3-(3-methyl-2-butenyl)-4H-6,6-dimethylpyrano- [2,3-h]-1-benzopyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one; 2-(2,4-Dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-butenyl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one, 9CI; 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-en-1-yl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one
Click to Show/Hide
|
||||
| Species Origin | Morus australis ... | Click to Show/Hide | |||
| Morus australis | |||||
| Disease | Renal cell carcinoma [ICD-11: 2C90] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C25H24O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(=CCC1=C(OC2=C(C1=O)C(=CC3=C2C=CC(O3)(C)C)O)C4=C(C=C(C=C4)O)O)C
|
||||
| InChI |
1S/C25H24O6/c1-13(2)5-7-17-22(29)21-19(28)12-20-16(9-10-25(3,4)31-20)24(21)30-23(17)15-8-6-14(26)11-18(15)27/h5-6,8-12,26-28H,7H2,1-4H3
|
||||
| InChIKey |
XFFOMNJIDRDDLQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 62596-29-6
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TRAIL-R2 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | ||
| LN-18 | CVCL_0392 | Glioblastoma | Homo sapiens | |||
| Experimental
Result(s) |
Morusin induces TRAIL sensitization by regulating EGFR and DR5 in human glioblastoma cells. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | CCAAT/enhancer binding beta (CEBPB) | Molecule Info | [3] | |
| PPAR-gamma (PPARG) | Molecule Info | [3] | ||
| KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
| 2 | AMPK signaling pathway | |||
| 3 | Osteoclast differentiation | |||
| 4 | Huntington's disease | |||
| 5 | Pathways in cancer | |||
| 6 | Transcriptional misregulation in cancer | |||
| 7 | Thyroid cancer | |||
| 8 | TNF signaling pathway | |||
| 9 | Tuberculosis | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| 3 | Leptin Signaling Pathway | |||
| 4 | IL4 Signaling Pathway | |||
| Panther Pathway | CCKR signaling map ST | Click to Show/Hide | ||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | Click to Show/Hide | ||
| 2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 3 | Signaling events mediated by HDAC Class I | |||
| 4 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 5 | Regulation of retinoblastoma protein | |||
| 6 | Regulation of nuclear SMAD2/3 signaling | |||
| 7 | IL4-mediated signaling events | |||
| 8 | FOXA2 and FOXA3 transcription factor networks | |||
| 9 | IFN-gamma pathway | |||
| 10 | IL3-mediated signaling events | |||
| 11 | IL6-mediated signaling events | |||
| 12 | C-MYB transcription factor network | |||
| 13 | Validated nuclear estrogen receptor alpha network | |||
| 14 | Signaling mediated by p38-alpha and p38-beta | |||
| 15 | FOXA1 transcription factor network | |||
| Reactome | PPARA activates gene expression | Click to Show/Hide | ||
| 2 | Transcriptional regulation of white adipocyte differentiation | |||
| 3 | Nuclear Receptor transcription pathway | |||
| 4 | Senescence-Associated Secretory Phenotype (SASP) | |||
| WikiPathways | Wnt Signaling Pathway Netpath | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Differentiation of white and brown adipocyte | |||
| 4 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 5 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 6 | Adipogenesis | |||
| 7 | SREBP signalling | |||
| 8 | Nuclear Receptors | |||
| 9 | SIDS Susceptibility Pathways | |||
| 10 | Senescence and Autophagy in Cancer | |||
| 11 | Diurnally Regulated Genes with Circadian Orthologs | |||
| 12 | IL-4 Signaling Pathway | |||
| 13 | Ovarian Infertility Genes | |||
| 14 | Transcriptional activation by NRF2 | |||
| 15 | Oncostatin M Signaling Pathway | |||
| 16 | IL17 signaling pathway | |||
| 17 | miR-targeted genes in muscle cell - TarBase | |||
| 18 | miR-targeted genes in lymphocytes - TarBase | |||
| 19 | miR-targeted genes in leukocytes - TarBase | |||
| 20 | miR-targeted genes in epithelium - TarBase | |||
| 21 | miR-targeted genes in adipocytes - TarBase | |||
| 22 | Folate-Alcohol and Cancer Pathway | |||
